Sildenafil Teva
From £3.99
Clinical Evidence for Sildenafil Treatment
Established Research on Oral Sildenafil
The clinical evidence for sildenafil in treating erectile dysfunction is extensive, with over two decades of peer-reviewed research. Initial pivotal trials demonstrated that oral sildenafil significantly improved erectile function compared to placebo, with efficacy rates ranging from 70-80% across diverse patient populations. These studies formed the foundation for regulatory approval and established sildenafil as a first-line treatment option.
Mechanism of Action Research
Research has thoroughly established sildenafil's mechanism as a phosphodiesterase type 5 (PDE5) inhibitor. Clinical studies demonstrate that by blocking PDE5, sildenafil enhances the effects of nitric oxide, leading to smooth muscle relaxation and increased blood flow to penile tissue during sexual arousal. This mechanism has been validated through numerous pharmacological studies and imaging research.
Safety Profile Evidence
Extensive post-marketing surveillance and clinical trials have established sildenafil's safety profile. Large-scale studies involving thousands of patients have demonstrated that sildenafil is generally well-tolerated when used appropriately. Common side effects reported in clinical trials include headache, flushing, and nasal congestion, typically mild to moderate in severity. Cardiovascular safety studies have shown that sildenafil can be used safely in most men with stable cardiovascular disease, though contraindications exist with nitrate medications.
Comparative Effectiveness Research
Head-to-head clinical trials have compared sildenafil with other PDE5 inhibitors, demonstrating comparable efficacy across the class. Research indicates that individual response may vary, with some patients responding better to different medications within the same class. These studies support a personalised approach to treatment selection.
Alternative Formulation Research
While oral sildenafil remains the standard, researchers continue investigating alternative delivery methods, including topical formulations. Preliminary studies on gel formulations examine potential advantages such as localised action and reduced systemic exposure. However, most research in this area remains in early phases, with oral formulations maintaining the strongest evidence base.
Available Treatment Options
At EverydayMeds, patients can choose between branded Viagra and generic sildenafil tablets following clinical assessment. Both contain the same active ingredient and demonstrate equivalent efficacy in clinical studies. The choice between branded and generic options allows patients to select based on personal preference and cost considerations, with both backed by the same robust evidence base.
Real-World Evidence
Beyond clinical trials, real-world studies have confirmed sildenafil's effectiveness in routine clinical practice. These studies demonstrate sustained efficacy and acceptable tolerability across diverse patient populations, supporting the medication's role in standard erectile dysfunction management. Long-term safety data continues to support sildenafil's favourable benefit-risk profile when prescribed appropriately.
